1. OS1.7 Genomic attributes of tumor evolution and treatment response in diffuse glioma. (19th September 2018) Authors: Lin, A L; Jonsson, P; Ogilvie, S; Chavan, S; Nolan, C; Gavrilovic, I; Kaley, T; Grommes, C; Pentsova, E; Diamond, E; Daras, M; Stone, J; DeAngelis, L; Tabar, V; Brennan, C; Young, R J; Rosenblum, M; Taylor, B S; Mellinghoff, I K Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1. (6th September 2019) Authors: Mellinghoff, I K; Wen, P Y; Taylor, J W; Maher, E A; Arrillaga-Romany, I; Peters, K B; Le, K; Tai, F; Steelman, L; Cloughesy, T F Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗